Michael Morrissey
Overview
Explore the profile of Michael Morrissey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leblanc C, Rasanen K, Morrissey M, Skulason S, Ferguson M, Kristjansson B
BMC Ecol Evol
. 2024 Apr;
24(1):45.
PMID: 38622503
Background: A major goal in evolutionary biology is to understand the processes underlying phenotypic variation in nature. Commonly, studies have focused on large interconnected populations or populations found along strong...
2.
Cristescu R, Nebozhyn M, Zhang C, Albright A, Kobie J, Huang L, et al.
Clin Cancer Res
. 2021 Dec;
28(8):1680-1689.
PMID: 34965943
Purpose: To explore relationships between biological gene expression signatures and pembrolizumab response. Experimental Design: RNA-sequencing data on baseline tumor tissue from 1,188 patients across seven tumor types treated with pembrolizumab...
3.
Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, et al.
Endocr Relat Cancer
. 2019 Jan;
26(4):391-403.
PMID: 30667365
Neuroendocrine tumors (NETs) have historically been subcategorized according to histologic features and the site of anatomic origin. Here, we characterize the genomic alterations in patients enrolled in 3 phase 3...
4.
Orlando E, Han X, Tribouley C, Wood P, Leary R, Riester M, et al.
Nat Med
. 2018 Oct;
24(10):1504-1506.
PMID: 30275569
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19 relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority...
5.
Islam I, Yuan S, Wei R, Xu W, Morrissey M, Mohan R, et al.
Bioorg Med Chem Lett
. 2018 Apr;
28(9):1459-1463.
PMID: 29628327
A hit to lead process to identify reversible, orally available ADP receptor (P2Y) antagonists lead compounds is described. High throughput screening afforded 1. Optimization of 1, using parallel synthesis methods,...
6.
de Villemereuil P, Schielzeth H, Nakagawa S, Morrissey M
Genetics
. 2016 Sep;
204(3):1281-1294.
PMID: 27591750
Methods for inference and interpretation of evolutionary quantitative genetic parameters, and for prediction of the response to selection, are best developed for traits with normal distributions. Many traits of evolutionary...
7.
Morrissey M, Ciorciari A, Cunningham S
Pediatr Emerg Care
. 2016 Jun;
32(6):388-9.
PMID: 27257741
The presentation of acute-onset hemiparesis in a teenager can be challenging and offers a wide differential diagnosis. We discuss the approach to the patient (which should begin with thorough history...
8.
Mirzaa G, Campbell C, Solovieff N, Goold C, Jansen L, Menon S, et al.
JAMA Neurol
. 2016 May;
73(7):836-845.
PMID: 27159400
Importance: Focal cortical dysplasia (FCD), hemimegalencephaly, and megalencephaly constitute a spectrum of malformations of cortical development with shared neuropathologic features. These disorders are associated with significant childhood morbidity and mortality....
9.
Brannon A, Frizziero M, Chen D, Hummel J, Gallo J, Riester M, et al.
Cold Spring Harb Mol Case Stud
. 2016 May;
2(2):a000620.
PMID: 27148582
The mTORC1 inhibitor everolimus (Afinitor/RAD001) has been approved for multiple cancer indications, including ER(+)/HER2(-) metastatic breast cancer. However, the combination of everolimus with the dual PI3K/mTOR inhibitor BEZ235 was shown...
10.
Kaur K, Zheng N, Smith K, Huang M, Li L, Pauli N, et al.
PLoS One
. 2015 May;
10(5):e0125618.
PMID: 25951191
Breakdown of B cell tolerance is a cardinal feature of systemic lupus erythematosus (SLE). Increased numbers of autoreactive mature naïve B cells have been described in SLE patients and autoantibodies...